The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close contact with someone who is infected vulnerable to developing COVID ...
That’s the potential promise of a new study on a drug made by Japanese pharmaceutical company Shionogi. At a scientific ...
An open letter to US Secretary of State Marco Rubio signed by hundreds of high-profile HIV doctors, researchers and public ...
Hundreds of HIV doctors and researchers have called on the Trump administration to reverse its sweeping aid funding cuts, ...
Japan’s Shionogi (TYO: 4507) yesterday delivered a late-breaking scientific oral presentation at the Conference of ...
New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the ...
An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback